HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel
NRx Pharmaceuticals (NASDAQ:NRXP) and its subsidiary HOPE Therapeutics announced that Dr. David Feifel, founder of Kadima Neuropsychiatry Institute, was featured on CNN's program "'Special K': The Science & Stigma of Ketamine" hosted by Dr. Sanjay Gupta. Kadima is identified as HOPE's planned flagship clinic acquisition, pending completion of financial audits and standard closing conditions.
Dr. Feifel, who is set to become HOPE's Chief Medical Innovation Officer following the planned acquisition, advocated for ketamine use in appropriate patients under proper psychiatric supervision in a controlled setting. This follows his previous appearance on Dr. Gupta's program "The Wild West of Ketamine Treatment" in August. Dr. Feifel emphasized the importance of providing access to psychiatric centers of excellence for depression treatment using ketamine and other advanced therapies under high medical care standards.
NRx Pharmaceuticals (NASDAQ:NRXP) e la sua filiale HOPE Therapeutics hanno annunciato che il Dr. David Feifel, fondatore del Kadima Neuropsychiatry Institute, è stato ospite nel programma della CNN "'Special K': La Scienza e lo Stigma del Ketamina", condotto dal Dr. Sanjay Gupta. Kadima è identificata come l'acquisizione principale pianificata da HOPE, in attesa del completamento delle verifiche finanziarie e delle condizioni standard di chiusura.
Il Dr. Feifel, che diventerà il Chief Medical Innovation Officer di HOPE dopo l'acquisizione pianificata, ha sostenuto l'uso del ketamina in pazienti appropriati sotto la giusta supervisione psichiatrica in un contesto controllato. Questo segue la sua precedente apparizione nel programma del Dr. Gupta "Il Far West del Trattamento con Ketamina" in agosto. Il Dr. Feifel ha sottolineato l'importanza di fornire accesso a centri psichiatrici di eccellenza per il trattamento della depressione utilizzando il ketamina e altre terapie avanzate, sotto elevati standard di assistenza medica.
NRx Pharmaceuticals (NASDAQ:NRXP) y su filial HOPE Therapeutics anunciaron que el Dr. David Feifel, fundador del Kadima Neuropsychiatry Institute, fue destacado en el programa de CNN "'Special K': La Ciencia y el Estigma de la Ketamina", presentado por el Dr. Sanjay Gupta. Kadima se identifica como la adquisición principal planificada por HOPE, pendiente de la finalización de auditorías financieras y de las condiciones estándar de cierre.
El Dr. Feifel, que se convertirá en el Chief Medical Innovation Officer de HOPE tras la adquisición planificada, abogó por el uso de la ketamina en pacientes apropiados bajo la supervisión psiquiátrica adecuada en un entorno controlado. Esto sigue su aparición anterior en el programa del Dr. Gupta "El Lejano Oeste del Tratamiento con Ketamina" en agosto. El Dr. Feifel enfatizó la importancia de proporcionar acceso a centros psiquiátricos de excelencia para el tratamiento de la depresión utilizando la ketamina y otras terapias avanzadas bajo altos estándares de atención médica.
NRx Pharmaceuticals (NASDAQ:NRXP)와 그 자회사 HOPE Therapeutics는 카디마 신경정신의학 연구소의 설립자인 David Feifel 박사가 Sanjay Gupta 박사가 진행하는 CNN 프로그램 "'Special K': 케타민의 과학과 오명"에 출연했다고 발표했습니다. 카디마는 HOPE의 주요 클리닉 인수 예정으로, 재무 감사 완료 및 표준 마감 조건을 기다리고 있습니다.
Feifel 박사는 예정된 인수 후 HOPE의 Chief Medical Innovation Officer가 될 예정이며, 적절한 환자에게 통제된 환경에서 적절한 정신과 감독 하에 케타민 사용을 지지했습니다. 이는 8월 Gupta 박사의 프로그램 "케타민 치료의 황야"에 출연한 것에 이어지는 것입니다. Feifel 박사는 높은 의료 기준 하에 케타민과 기타 첨단 요법을 사용한 우울증 치료를 위한 정신과 전문센터 접근의 중요성을 강조했습니다.
NRx Pharmaceuticals (NASDAQ:NRXP) et sa filiale HOPE Therapeutics ont annoncé que le Dr David Feifel, fondateur de l'Institut de neuropsychiatrie Kadima, a été présenté dans le programme de CNN "'Special K': La Science et le Stigma du Kétamine", animé par le Dr Sanjay Gupta. Kadima est identifié comme l'acquisition phare prévue de HOPE, en attente de l'achèvement des audits financiers et des conditions standard de clôture.
Le Dr Feifel, qui doit devenir le Chief Medical Innovation Officer de HOPE après l'acquisition prévue, a plaidé en faveur de l'utilisation du kétamine chez les patients appropriés sous une supervision psychiatrique adéquate dans un cadre contrôlé. Cela fait suite à sa précédente apparition dans le programme du Dr Gupta "Le Far West du Traitement par Kétamine" en août. Le Dr Feifel a souligné l'importance de fournir un accès à des centres psychiatriques d'excellence pour le traitement de la dépression utilisant le kétamine et d'autres thérapies avancées, sous de hauts standards de soin médical.
NRx Pharmaceuticals (NASDAQ:NRXP) und deren Tochtergesellschaft HOPE Therapeutics haben bekannt gegeben, dass Dr. David Feifel, Gründer des Kadima Neuropsychiatry Institute, in der CNN-Sendung "'Special K': Die Wissenschaft und das Stigma von Ketamin", moderiert von Dr. Sanjay Gupta, vorgestellt wurde. Kadima wird als die geplante Flagship-Klinikübernahme von HOPE identifiziert, vorbehaltlich des Abschlusses finanzieller Prüfungen und der üblichen Abschlussbedingungen.
Dr. Feifel, der nach der geplanten Übernahme zum Chief Medical Innovation Officer von HOPE ernannt werden soll, trat für den Einsatz von Ketamin bei geeigneten Patienten unter angemessener psychiatrischer Aufsicht in einem kontrollierten Umfeld ein. Dies folgt seinem vorherigen Auftritt in Dr. Guptas Programm "Der Wilde Westen der Ketaminbehandlung" im August. Dr. Feifel betonte die Bedeutung eines Zugangs zu psychiatrischen Zentren von höchster Qualität für die Behandlung von Depressionen mit Ketamin und anderen modernen Therapien unter hohen medizinischen Standards.
- Planned acquisition of Kadima Neuropsychiatry Institute, an industry gold-standard clinic
- Appointment of Dr. David Feifel, a global leader in interventional psychiatry, as future Chief Medical Innovation Officer
- None.
Insights
The CNN coverage featuring Dr. Feifel and Dr. Gupta discussing ketamine treatment represents a neutral media event without direct material impact on NRXP's current operations or financials. While the planned acquisition of Kadima Neuropsychiatry Institute and Dr. Feifel's future role as Chief Medical Innovation Officer are mentioned, these are still pending completion of audits and closing conditions.
The media appearance primarily focuses on educational aspects of ketamine treatment and safety protocols, rather than announcing any new business developments, partnerships, or financial implications. The discussion of Matthew Perry's death and ketamine treatment standards, while relevant to the broader industry dialogue, does not materially affect NRXP's immediate business prospects or market position.
From a clinical perspective, while Dr. Feifel's expertise and Kadima's reputation as a gold-standard facility are valuable assets, their impact remains speculative until the acquisition closes. The emphasis on proper psychiatric supervision aligns with industry best practices but doesn't introduce new protocols or business opportunities that would significantly affect NRXP's valuation or market performance.
- "'Special K': The Science & Stigma of Ketamine" on CNN, hosted by Dr. Sanjay Gupta
- David Feifel MD PHD, Founder of Kadima, is a global thought leader in the interventional psychiatry field
- Kadima Neuropsychiatry Institute identified as planned HOPE Flagship Clinic pending acquisition closing
- Dr. Feifel is expected to join HOPE as Chief Medical Innovation Officer
Dr. Feifel, a global leader in interventional psychiatry, has accepted a future role as Chief Medical Innovation Officer in conjunction with the previously announced planned acquisition of Kadima by HOPE. The acquisition is subject to completion of financial audits and standard closing conditions.
In his comments, Dr. Feifel supported use the of ketamine in appropriate patients but emphasized the need for appropriate psychiatric supervision in a controlled setting - a view that HOPE wholeheartedly shares. This appearance with Dr. Gupta follows his appearance on another of Dr. Gupta's programs, "The Wild West of Ketamine Treatment" in August of last year.
"The recent, tragic death of Mathew Perry underscores the need for people with depression to have access to psychiatric centers of excellence where they can receive ketamine and other advanced treatments at the highest standard of medical care," said David Feifel. "I plan to bring this same vision for use of ketamine and other interventional psychiatry treatment methods that made my clinic, Kadima, an industry gold-standard, to the HOPE network, upon joining the Company."
About HOPE Therapeutics, Inc.
HOPE Therapeutics, Inc. (www.hopetherapeutics.com) is a development stage healthcare delivery company that intends to develop a best-in-class network of interventional psychiatry clinics to offer ketamine transcranial magnetic stimulation (TMS) and other lifesaving therapies to patients with suicidal depression and related disorders, together with a digital therapeutic-enabled platform designed to augment and preserve the clinical benefit of NMDA-targeted drug therapy.
About NRx Pharmaceuticals, Inc.
NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRX-101 additionally has potential to act as a non-opioid treatment for chronic pain, as well as a treatment for complicated UTI.
NRx has recently announced initiation of filing a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality.
Notice Regarding Forward-Looking Statements
The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, among others, statements regarding closing the acquisition of Kadima and obtaining financing necessary to consummate the acquisition. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "may," "will," "should," "would," "expect," "plan," "believe," "intend," "look forward," and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, liquidity, Hope Therapeutic's ability to consummate the acquisitions of providers for its national network, the Company's ability to raise adequate capital to fund the Hope Therapeutics acquisitions, and the Company's ability to spin-off Hope Therapeutics. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. Except as may be required by applicable law, The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise.
For further information:
Matthew Duffy
Chief Business Officer, NRx Pharmaceuticals
Co-Chief Executive Officer, HOPE Therapeutics, Inc.
mduffy@nrxpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/hope-therapeutics-inc-and-nrx-pharmaceuticals-inc-nasdaqnrxp-alert-investors-to-sanjay-guptacnn-program-on-ketamine-featuring-kadima-neuropsychiatry-institute-founder-dr-david-feifel-302350245.html
SOURCE NRx Pharmaceuticals, Inc.
FAQ
What is the status of NRXP's acquisition of Kadima Neuropsychiatry Institute?
What role will Dr. David Feifel take at HOPE Therapeutics after NRXP's acquisition of Kadima?
What was Dr. Feifel's stance on ketamine treatment in the CNN program?
How many CNN appearances has Dr. Feifel made regarding ketamine treatment?
